Ann: Trading Halt, page-19

A snippet from the 2020 AGM, (Revisit the 2020 AGM Presentation for clarity) There is a lot to like

VALUE PROPOSITION:Manufacturer of regulatory cleared medical devices (SaMD)
5 Regulatory Cleared Services
Targeting FDA clearance on second AI solution, HepaFat-AI

DiverseR&DPipeline
Artificial Intelligence
Imaging
Molecular Medicine

Growing Revenue
Services being used in 9 active clinical trials
Increased revenue despite impact from COVID-19
4 channel partners for distribution of AI product

Strong Balance Sheet
Cash balance of $7.5m
Cash flow positive from the last 10 consecutive quarters
Company has no debt